纳武利尤单抗联合仑伐替尼治疗不可切除肝细胞癌的II期转化研究
IMMUNIB单臂II期试验评估纳武利尤单抗联合仑伐替尼一线治疗不可切除肝细胞癌,49例可评估患者ORR为32%,中位PFS 9.0个月,中位OS 26.6个月,未达到预设ORR≥43%的主要终点,但观察到持久缓解和生存获益,转化分析提示FGFR激活及免疫炎症特征与疗效相关。
要点
- 联合方案ORR 32%,中位PFS 9.0个月,中位OS 26.6个月。
- 未达到预设主要终点ORR≥43%,但部分患者持久缓解。
- FGFR激活及免疫炎症特征可能与治疗获益相关。
核心结论
- 联合方案未达到预设ORR≥43%的主要终点,但显示鼓舞性的临床活性、持久缓解和总生存延长。
- 鉴于单臂设计,结果应视为探索性,支持进一步研究TKI/ICI联合及生物标志物驱动选择策略。
研究设计与样本
- 研究者发起的单臂II期试验,纳入不可切除肝细胞癌一线治疗患者,接受仑伐替尼联合纳武利尤单抗最长18个月或直至疾病进展/不可耐受毒性。
- 共入组50例,49例接受至少一剂联合治疗(24例BCLC-B,18例BCLC-C,7例不可评估)。
- 主要终点为RECIST v1.1评估的客观缓解率(ORR),预设零假设ORR为24%,检验效能可检测43%的ORR。
主要发现
- ORR为32%(95% CI 19.5–46.7)。
- 中位无进展生存期(PFS)为9.0个月,中位总生存期(OS)为26.6个月。
- 末次随访时17例患者仍存活,其中2例仍无进展。
- 复发≥5%的≥3级治疗相关不良事件包括结肠炎、腹泻、高血压和胆红素升高。
- 探索性转化分析显示FGFR激活以及免疫和炎症特征与治疗获益相关。
临床怎么用
- 该联合方案在部分不可切除肝细胞癌一线患者中显示持久缓解和生存获益,但ORR未达预设阈值。
- 治疗相关≥3级不良事件需关注结肠炎、腹泻、高血压和胆红素升高。
- FGFR激活及免疫炎症特征可能作为潜在生物标志物指导患者选择,但需进一步验证。
局限性
- 单臂设计,结果应视为探索性。
- 样本量有限(49例接受治疗),结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combinations of anti-angiogenic agents, including lenvatinib, and PD-1/PD-L1 inhibitors have demonstrated antitumor activity with manageable toxicity in several tumor types, including hepatocellular carcinoma (HCC). OBJECTIVE: The IMMUNIB trial aimed to evaluate efficacy of nivolumab in combination with lenvatinib as first-line treatment in patients with unresectable HCC. DESIGN: This investigator-initiated single-arm phase-2 trial enrolled patients with advanced stage HCC for first-line therapy who were treated with lenvatinib plus nivolumab for a maximum of 18 months or until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) according to RECIST v1.1. The study was powered to detect an ORR of 43% using a prespecified null hypothesis ORR of 24%Secondary endpoints included time to progression (TTP), progression free survival (PFS), overall survival (OS) and safety. RESULTS: Out of 50 enrolled patients, 49 received at least one dose of the combination treatment (24 BCLC-B, 18 BCLC-C, 7 not evaluable). The ORR was 32% [95% CI 19.5,46.7]. Median PFS was 9.0 months, and the median OS was 26.6 months. Notably, 17 patients were still alive at the last follow-up, with 2 remaining progression-free. Recurrent (≥5%) treatment related adverse events grade ≥ 3 included colitis, diarrhea, hypertension and elevated bilirubin. Exploratory translational analysis using plasma-based epigenomic and tissue-based transcriptome profiling indicated a correlation between FGFR activation as well as immune- and inflammatory signatures and treatment benefits. CONCLUSION: Although the study did not meet its prespecified primary endpoint of an ORR ≥ 43%, the combination of lenvatinib and nivolumab demonstrated encouraging clinical activity with durable responses and prolonged overall survival in a subset of patients. Given the single-arm design, these find-ings should be considered exploratory and support further investigation of TKI/ICI combinations and biomarker-driven patient selection strategies in HCC.
引用
- Vogel A, Ben Khaled N, Ramirez JR, et al. Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study. Eur J Cancer. 2026. PMID: 42284972. doi:10.1016/j.ejca.2026.116847
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。